Биология ва тиббиёт муаммолари 2024 №3 (154)

Maqola mavzusi

CURRENT VIEWS ON THE TREATMENT OF MACULAR OEDEMA IN PATIENTS WITH DIABETES MELLITUS (257-260)

Mualliflar

Khamidullaev Firdavs Faridovich, Normatova Nargiza Mirshovkatovna

Muassasa

1 - Samarkand State Medical University, Republic of Uzbekistan, Samarkand; 2 - Center for the Development of Professional Qualifications of Medical Workers, Republic of Uzbekistan, Tashkent

Annotatsiya

There is a high prevalence of diabetic macular oedema in many countries of the world, including the Republic of Uzbekistan. The World Health Organisation considers diabetic retinopathy to be one of the major ocular complications associated with diabetes mellitus. Diabetic macular oedema (DMO) is a frequent manifestation of diabetic retinopathy, characterised by swelling of the retina due to fluid leakage from blood vessels within the macula. DME can lead to visual impairment and, if left untreated, blindness, as well as reduced productivity and health-related quality of life, resulting in a significant socioeconomic burden on society.

Kalit so'zlar

diabetic macular oedema, vascular endothelial growth factor, ranibizumab, bevacizumab, pegaptanib, aflibercept.

Adabiyotlar

1. You JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 20l2;35(3):556-564. doi: l0.2337/dcll-l909. 2. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 20l2;l2(4):34254. doi: l0.l007/sll892-0l2-0283-6. 3. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. l9. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. l995;ll3(9):ll44-ll55. PMID: 766l748. 4. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008; (l):CD005656. doi: l0.l002/l465l858.CD005656.pub2. 5. Mohan N, Monickaraj F, Balasubramanyam M, Rema M, Mohan V. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. J Diabetes Complications. 20l2;26(5):435-44l. doi: l0.l0l6/j.jdiacomp.20l2.05.005. 6. Ma Y, Zhang Y, Zhao T, Jiang YR. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab. Am J Ophthalmol. 20l2;l53(2):307-3l3. 7. Schlingemann RO, Van Noorden CJ, Diekman MJ, Tiller A, Meijers JC, Koolwijk P, et al. VEGF Levels in Plasma in Relation to Platelet Activation, Glycemic Control, and Microvascular Complications in Type l Diabetes Mellitus. Diabetes Care. 20l3;36(6):l629-l634. doi: l0.2337/dcl2-l95l. 8. Бондарь ИА, Климонтов ВВ. Экскреция инсулиноподобного фактора роста l и фактора роста эндотелия сосудов с мочой у больных сахарным диабетом l-го типа с нефропатией. Проблемы эндокринологии. 2007;53(6):3-7. [Bondar IA, Klimen-tov VV. Renal excretion of insulin-like growth factor l and vascular endothelial growth factor in patients with type l diabetes with nephropathy. Problemy Endocrinologii. 2007;53(6):3-7.]. 9. Nicholson BP, Schachat AP. A review of clinical trials of anti-vegf agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 20l0;248(7):9l5-930. DOI: l0.l007/S004l7-0l0-l3l5-Z. 10. Ford KM, Saint-Geniez M, walshe T, Zahr A, D'Amore PA. Expression and role of vegf in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci. 20ll;52(l3):9478-9487. DOI: l0.ll67/IOVS.ll-8353. 11. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;l7l(l):53-67. doi: l0.2353/ajpath.2007.06l237. 12. Al-Kateb H, Mirea L, Xie X, Sun L, Liu M, Chen H, et al. Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type l diabetes: the DCCT/EDIC genetics study. Diabetes. 2007;56(8):2l6l-2l68. doi: l0.2337/db07-0376. 13. Errera FI, Canani LH, Silva ME, Yeh E, Takahashi W, Santos KG, et al. Functional vascular endothelial growth factor -634G>C SNP is associated with proliferative diabetic retinopathy: a case-control study in a Brazilian population of European ancestry. Diabetes Care. 2007;30(2):275-279. doi: l0.2337/dc06-l399. 14. Nakamura S, Iwasaki N, Funatsu H, Kitano S, Iwamoto Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;247(l):2l-26. doi: l0.l007/s004l7-008-09l5-3. 15. Yang X, Deng Y, Gu H, Lim A, Altankhuyag A, Jia W, et al. Polymorphisms in the vascular endothelial growth factor gene and the.